Evidence map›Paper›PMID 40688336›Full record

ArticleJournal of thoracic disease2025

Identification and validation of a prognostic signature of m

Zhengrong Huang, Ying Peng, Siqian Cai, Liyan Wang, Hanwen Lin, Jiaying Qiu, Yaqi Wen, Yixin Chen, Yuanmei Chen, Yuanji Xu and 3 more

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bioinformatics analysis identifiesTranslational cancer research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhengrong Huang *Department of Integrative Traditional Chinese and Western Medicine, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Ying Peng *Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Siqian CaiDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Liyan WangDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Hanwen LinThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Jiaying QiuThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Yaqi WenThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Yixin ChenThe School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Yuanmei ChenDepartment of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Yuanji XuDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zhizhong LinDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Jingjing DongDepartment of General Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Haiyan PengDepartment of Clinical Laboratory, The First Hospital of Putian City, Putian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Esophageal cancer (ESCA) is one of the most common malignancies, and has a poor prognosis. The role of 5-methylcytosine (m Methods: Based on the expression of the m Results: The m Conclusions: Two subtypes of m

Indexed as

5-methylcytosine regulators (m5C regulators)Esophageal cancer (ESCA)nomogramprognostic model

Identifiers

PMID40688336
PMCPMC12268704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.